Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11476 - 11500 of 11650 in total
ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.
Investigational
Investigational
Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.
Investigational
Investigational
Ubenimex (also known as bestatin) is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.
Investigational
Matched Description: … Ubenimex (also known as bestatin) is a competitive protease inhibitor. …
IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ T cell platform
Investigational
Matched Description: … IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens …
Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis . The drug made it to phase III trials before abandoned due to increased stroke.
Investigational
Matched Description: … Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment …
Foliglurax is under investigation in clinical trial NCT02639221 (A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects).
Investigational
Matched Description: … Foliglurax is under investigation in clinical trial NCT02639221 (A Phase I, Double Blind, Placebo Controlled …
Mezigdomide is under investigation in clinical trial NCT05372354 (A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma).
Investigational
Matched Description: … Mezigdomide is under investigation in clinical trial NCT05372354 (A Study to Evaluate Safety, Drug Levels …
SM-1997 is a protein-free solution derived from calf's blood comprising electrolytes, trace minerals, amino acids, peptides, nucleosides, and nucleotides. It is under investigation for the treatment of cutaneous sulfur mustard-induced injury.
Investigational
Matched Description: … SM-1997 is a protein-free solution derived from calf's blood comprising electrolytes, trace minerals, …
INCB13739 is developed as a new treatment for type 2 diabetes. It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes.
Investigational
Matched Description: … INCB13739 is developed as a new treatment for type 2 diabetes. …
CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis. The vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.
Investigational
Matched Description: … CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering …
Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).
Investigational
Matched Description: … Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics …
CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques. It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis, and vasculitis.
Investigational
Matched Description: … CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia …
SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).
Investigational
Matched Description: … It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating …
Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
Investigational
IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes. Trials of this drug have most likely...
Investigational
Matched Description: … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling …
Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders, and may be associated with disease activity. Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to...
Investigational
Matched Description: … Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha. …
Etilamfetamine is also known as N-ethylamphetamine and is in the Canadian Legislation - The Controlled Drugs and Substances Act, and is a Schedule 1 controlled drug. Like other amphetamines, this amphetamine analog was used as an appetite suppressant in the 1950s. However, being on the controlled drug and substance act...
Experimental
Matched Description: … N-ethylamphetamine and is in the Canadian Legislation - The Controlled Drugs and Substances Act, and is a
OT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye. It is intended to treat Age-related macular Degeneration (AMD), and preclinical research results indicate additional uses...
Investigational
Matched Description: … A leading cause of vision loss, AMD affects approximately 10 million Americans. ... OT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to …
Sulbutiamine is a synthetic derivative of thiamine (vitamin B1) under the market name Arcalion that is composed of two modified thiamine molecules to form a dimer. It is highly lipophilic, allowing it to cross the blood-brain barrier more easily than other thiamine derivatives. Although its clinical efficacy is not yet...
Experimental
Matched Description: … composed of two modified thiamine molecules to form a dimer. ... Sulbutiamine is a synthetic derivative of thiamine (vitamin B1) under the market name Arcalion that is …
Deoxyribonuclease I (DNase I) is a human enzyme responsible for the digestion of extracellular DNA7 . It is normally found in saliva, urine, pancreatic secretions, and blood . Because of the hypothesis that increased concentrations of high-molecular-weight DNA is a factor for airway obstruction, abnormal viscoelastic properties of the sputum,...
Investigational
Matched Description: … Deoxyribonuclease I (DNase I) is a human enzyme responsible for the digestion of extracellular DNA7[A227723 ... Because of the hypothesis that increased concentrations of high-molecular-weight DNA is a factor for …
MVA-BN-brachyury-TRICOM vaccine is an investigational cancer vaccine. It is composed of recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumour-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1...
Investigational
Matched Description: … MVA-BN), encoding the human transcription factor and tumour-associated antigen (TAA) brachyury, and a ... [L44513] MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration …
Thiodigalactoside is a solid. This compound belongs to the dihexoses. These are disaccharides containing two hexose carbohydrates. This medication is known to target galectin-1, heat-labile enterotoxin b chain, neurocan core protein, and lactose permease.
Experimental
Matched Description: … Thiodigalactoside is a solid. This compound belongs to the dihexoses. …
Displaying drugs 11476 - 11500 of 11650 in total